{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T17:59:45Z","timestamp":1792605585929,"version":"4.5.0"},"reference-count":96,"publisher":"MDPI AG","issue":"4","license":[{"start":{"date-parts":[[2022,2,10]],"date-time":"2022-02-10T00:00:00Z","timestamp":1644451200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cells"],"abstract":"<jats:p>The introduction of high-dose therapy in the 1990s as well as the development of drugs such as thalidomide, lenalidomide, and bortezomib in the 2000s led to an impressive improvement in outcome of patients with multiple myeloma (MM) eligible for autologous stem cell transplantation (ASCT). Clinical trials conducted in the first ten years of the twenty-first century established as standard therapy for these patients a therapeutic approach including induction, single or double ASCT, consolidation, and maintenance therapy. More recently, incorporating second-generation proteasome inhibitors carfilzomib and monoclonal antibody daratumumab into each phase of treatment significantly improved the efficacy of ASCT in terms of measurable residual disease (MRD) negativity, Progression Free Survival (PFS), and Overall Survival (OS). The availability of techniques such as multiparameter flow cytometry (MFC) and next-generation sequencing (NGS) for MRD assessment allowed the design of MRD-based response-adjusted trials that will define, in particular, the role of consolidation and maintenance therapies. In this review, we will provide an overview of the most recent evidence and the future prospects of ASCT in MM patients.<\/jats:p>","DOI":"10.3390\/cells11040606","type":"journal-article","created":{"date-parts":[[2022,2,10]],"date-time":"2022-02-10T04:42:27Z","timestamp":1644468147000},"page":"606","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":31,"title":["Autologous Stem Cell Transplantation in Multiple Myeloma: Where Are We and Where Do We Want to Go?"],"prefix":"10.3390","volume":"11","author":[{"given":"Sonia","family":"Mor\u00e8","sequence":"first","affiliation":[{"name":"Clinica di Ematologia, Azienda Ospedaliero-Universitaria Ospedali Riuniti di Ancona, 60126 Torrette, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Corvatta","sequence":"additional","affiliation":[{"name":"U.O.C. Medicina, Ospedale Engles Profili, 60044 Fabriano, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentina Maria","family":"Manieri","sequence":"additional","affiliation":[{"name":"Clinica di Ematologia, Azienda Ospedaliero-Universitaria Ospedali Riuniti di Ancona, 60126 Torrette, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6500-9514","authenticated-orcid":false,"given":"Francesco","family":"Saraceni","sequence":"additional","affiliation":[{"name":"Clinica di Ematologia, Azienda Ospedaliero-Universitaria Ospedali Riuniti di Ancona, 60126 Torrette, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilaria","family":"Scortechini","sequence":"additional","affiliation":[{"name":"Clinica di Ematologia, Azienda Ospedaliero-Universitaria Ospedali Riuniti di Ancona, 60126 Torrette, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giorgia","family":"Mancini","sequence":"additional","affiliation":[{"name":"Clinica di Ematologia, Azienda Ospedaliero-Universitaria Ospedali Riuniti di Ancona, 60126 Torrette, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Fiorentini","sequence":"additional","affiliation":[{"name":"Clinica di Ematologia, Azienda Ospedaliero-Universitaria Ospedali Riuniti di Ancona, 60126 Torrette, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Attilio","family":"Olivieri","sequence":"additional","affiliation":[{"name":"Clinica di Ematologia, Azienda Ospedaliero-Universitaria Ospedali Riuniti di Ancona, 60126 Torrette, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2749-7347","authenticated-orcid":false,"given":"Massimo","family":"Offidani","sequence":"additional","affiliation":[{"name":"Clinica di Ematologia, Azienda Ospedaliero-Universitaria Ospedali Riuniti di Ancona, 60126 Torrette, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,2,10]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Padala, S.A., Barsouk, A., Barsouk, A., Rawla, P., Vakiti, A., Kolhe, R., Kota, V., and Ajebo, G.H. (2021). Epidemiology, staging, and management of multiple myeloma. Med. Sci., 9.","DOI":"10.3390\/medsci9010003"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"2516","DOI":"10.1182\/blood-2007-10-116129","article-title":"Improved survival in multiple myeloma and the impact of novel therapies","volume":"111","author":"Kumar","year":"2008","journal-title":"Blood"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"2521","DOI":"10.1182\/blood-2007-08-104984","article-title":"Recent major improvement in long-term survival of younger patients with multiple myeloma","volume":"111","author":"Brenner","year":"2008","journal-title":"Blood"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1182\/bloodadvances.2019000524","article-title":"Long-term outcomes after autologous stem cell transplantation for multiple myeloma","volume":"4","author":"Nishimura","year":"2020","journal-title":"Blood Adv."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"3600","DOI":"10.1038\/s41375-021-01250-0","article-title":"Improved survival in multiple myeloma during the 2005\u20132009 and 2010\u20132014 periods","volume":"35","author":"Corre","year":"2021","journal-title":"Leukemia"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"840.e1","DOI":"10.1016\/j.jtct.2021.06.014","article-title":"Reduction in late mortality among patients with multiple myeloma treated with autologous peripheral blood stem cell transplantation\u2014A Blood or Marrow Transplant Survivor Study report","volume":"27","author":"Giri","year":"2021","journal-title":"Transpl. Cell Ther."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1200\/JCO.18.02096","article-title":"Treatment of multiple myeloma: ASCO and CCO joint clinical practice guideline","volume":"37","author":"Mikhael","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.annonc.2020.11.014","article-title":"EHA Guidelines Committee. Multiple myeloma: EHA-ESMO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"32","author":"Dimopoulos","year":"2021","journal-title":"Ann. Oncol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1056\/NEJM199607113350204","article-title":"A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Fran\u00e7ais du My\u00e9lome","volume":"335","author":"Attal","year":"1996","journal-title":"N. Engl. J. Med."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.1056\/NEJMoa022340","article-title":"High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma","volume":"348","author":"Child","year":"2003","journal-title":"N. Engl. J. Med."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"3052","DOI":"10.1182\/blood-2004-02-0408","article-title":"Intermediate-dose melphalan improves survival of myeloma patients aged 50 to 70: Results of a randomized controlled trial","volume":"104","author":"Palumbo","year":"2004","journal-title":"Blood"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"9227","DOI":"10.1200\/JCO.2005.03.0551","article-title":"High-dose therapy and autologous blood stem-cell transplantation compared with conventional treatment in myeloma patients aged 55 to 65 years: Long-term results of a randomized control trial from the Group Myelome-Autogreffe","volume":"23","author":"Fermand","year":"2005","journal-title":"J. Clin. Oncol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"3755","DOI":"10.1182\/blood-2005-03-1301","article-title":"High-dose therapy intensification compared with continued standard chemotherapy in multiple myeloma patients responding to the initial chemotherapy: Long-term results from a prospective randomized trial from the Spanish cooperative group PETHEMA","volume":"106","author":"Sureda","year":"2005","journal-title":"Blood"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1200\/JCO.2005.04.5807","article-title":"Standard chemotherapy compared with high-dose chemoradiotherapy for multiple myeloma: Final results of phase III US Intergroup Trial S9321","volume":"24","author":"Barlogie","year":"2006","journal-title":"J. Clin. Oncol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1056\/NEJMoa1402888","article-title":"Autologous transplantation and maintenance therapy in multiple myeloma","volume":"371","author":"Palumbo","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1016\/S1470-2045(15)00389-7","article-title":"Chemotherapy plus lenalidomide versus autologous transplantation, followed by lenalidomide plus prednisone versus lenalidomide maintenance, in patients with multiple myeloma: A randomised, multicentre, phase 3 trial","volume":"16","author":"Gay","year":"2015","journal-title":"Lancet Oncol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1056\/NEJMoa1611750","article-title":"Lenalidomide, bortezomib, and dexamethasone with transplantation for myeloma","volume":"376","author":"Attal","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"e456","DOI":"10.1016\/S2352-3026(20)30099-5","article-title":"Autologous haematopoietic stem-cell transplantation versus bortezomib-melphalan-prednisone, with or without bortezomib-lenalidomide-dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02\/HO95): A multicentre, randomised, open-label, phase 3 study","volume":"7","author":"Cavo","year":"2020","journal-title":"Lancet Haematol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1016\/S1470-2045(21)00535-0","article-title":"Carfilzomib with cyclophosphamide and dexamethasone or lenalidomide and dexamethasone plus autologous transplantation or carfilzomib plus lenalidomide and dexamethasone, followed by maintenance with carfilzomib plus lenalidomide or lenalidomide alone for patients with newly diagnosed multiple myeloma (FORTE): A randomised, open-label, phase 2 trial","volume":"22","author":"Gay","year":"2021","journal-title":"Lancet Oncol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.1016\/S0140-6736(10)61424-9","article-title":"GIMEMA Italian Myeloma Network Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem ell transplantation in newly diagnosed multiple myeloma: A randomised phase 3 study","volume":"376","author":"Cavo","year":"2010","journal-title":"Lancet"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1182\/blood-2012-02-408922","article-title":"Superiority of bortezomib, thalidomide, and dexamethasone (VTD) as induction pretransplantation therapy in multiple myeloma: A randomized phase 3 PETHEMA\/GEM study","volume":"120","author":"Oriol","year":"2012","journal-title":"Blood"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"2569","DOI":"10.1182\/blood-2016-01-693580","article-title":"VTD is superior to VCD prior to intensive therapy in multiple myeloma: Results of the prospective IFM2013-04 trial","volume":"127","author":"Moreau","year":"2016","journal-title":"Blood"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1200\/JCO.2011.39.5137","article-title":"Randomized phase II study of bortezomib, thalidomide, and dexamethasone with or without cyclophosphamide as induction therapy in previously untreated multiple myeloma","volume":"31","author":"Ludwig","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"iv52","DOI":"10.1093\/annonc\/mdx096","article-title":"ESMO Guidelines Committee. Multiple myeloma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"28","author":"Moreau","year":"2017","journal-title":"Ann. Oncol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1038\/s41408-020-0311-8","article-title":"Longer term follow-up of the randomized phase III trial SWOG S0777: Bortezomib, lenalidomide and dexamethasone vs. lenalidomide and dexamethasone in patients (Pts) with previously untreated multiple myeloma without an intent for immediate autologous stem cell transplant (ASCT)","volume":"10","author":"Durie","year":"2020","journal-title":"Blood Cancer J."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1182\/blood.2019000241","article-title":"Bortezomib, lenalidomide, and dexamethasone as induction therapy prior to autologous transplant in multiple myeloma","volume":"134","author":"Oriol","year":"2019","journal-title":"Blood"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1928","DOI":"10.1200\/JCO.19.02515","article-title":"Long-term follow-up results of lenalidomide, bortezomib, and dexamethasone induction therapy and risk-adapted maintenance approach in newly diagnosed multiple myeloma","volume":"38","author":"Joseph","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_28","first-page":"1","article-title":"Real-world long-term outcomes in multiple myeloma with VRD induction, Mel200-conditioned auto-HCT, and lenalidomide maintenance","volume":"22","author":"Gaballa","year":"2021","journal-title":"Leuk. Lymphoma"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"3245","DOI":"10.1182\/blood-2018-99-112659","article-title":"Integrated analysis of randomized controlled trials evaluating bortezomib + lenalidomide + dexamethasone or bortezomib + thalidomide + dexamethasoneinduction in transplant-eligible newly diagnosed multiple myeloma","volume":"132","author":"Rosinol","year":"2018","journal-title":"Blood"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1016\/S1470-2045(20)30452-6","article-title":"Carfilzomib or bortezomib in combination with lenalidomide and dexamethasone for patients with newly diagnosed multiple myeloma without intention for immediate autologous stem-cell transplantation (ENDURANCE): A multicentre, open-label, phase 3, randomised, controlled trial","volume":"21","author":"Kumar","year":"2020","journal-title":"Lancet Oncol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"2513","DOI":"10.1182\/blood.2020007522","article-title":"Carfilzomib, lenalidomide, and dexamethasone plus transplant in newly diagnosed multiple myeloma","volume":"136","author":"Jasielec","year":"2020","journal-title":"Blood"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1182\/blood.2021010744","article-title":"Up-front carfilzomib, lenalidomide, and dexamethasone with transplant for patients with multiple myeloma: The IFM KRd final results","volume":"138","author":"Roussel","year":"2021","journal-title":"Blood"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0140-6736(19)31240-1","article-title":"Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): A randomised, open-label, phase 3 study","volume":"394","author":"Moreau","year":"2019","journal-title":"Lancet"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1182\/blood.2020005288","article-title":"Daratumumab, lenalidomide, bortezomib, and dexamethasone for transplant-eligible newly diagnosed multiple myeloma: The GRIFFIN trial","volume":"136","author":"Voorhees","year":"2020","journal-title":"Blood"},{"key":"ref_35","first-page":"01935","article-title":"Daratumumab, carfilzomib, lenalidomide, and dexamethasone with minimal residual disease response-adapted therapy in newly diagnosed multiple myeloma","volume":"13","author":"Costa","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1001\/jamaoncol.2021.0611","article-title":"Safety and effectiveness of weekly carfilzomib, lenalidomide, dexamethasone, and daratumumab combination therapy for patients with newly diagnosed multiple myeloma: The MANHATTAN nonrandomized clinical trial","volume":"7","author":"Landgren","year":"2021","journal-title":"JAMA Oncol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1182\/blood-2021-146040","article-title":"Daratumumab plus ixazomib, lenalidomide, and dexamethasone as extended induction and consolidation followed by lenalidomide maintenance in standard-risk transplant-eligible newly diagnosed multiple myeloma (NDMM) patients (IFM 2018-01): A phase II study of the Intergroupe Francophone Du My\u00e9lome (IFM)","volume":"138","author":"Perrot","year":"2021","journal-title":"Blood"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1182\/blood-2021-145097","article-title":"Addition of isatuximab to lenalidomide, bortezomib and dexamethasone as induction therapy for newly-diagnosed, transplant-eligible multiple myeloma patients: The phase III GMMG-HD7 trial","volume":"138","author":"Goldschmidt","year":"2021","journal-title":"Blood"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1182\/blood-2021-147323","article-title":"Elotuzumab in combination with lenalidomide, bortezomib, dexamethasone and autologous transplantation for newly-diagnosed multiple myeloma: Results from the randomized phase III GMMG-HD6 trial","volume":"138","author":"Goldschmidt","year":"2021","journal-title":"Blood"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/j.bbmt.2013.10.013","article-title":"Optimizing autologous stem cell mobilization strategies to improve patient outcomes: Consensus guidelines and recommendations","volume":"20","author":"Giralt","year":"2014","journal-title":"Biol. Blood Marrow Transpl."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.clml.2021.07.030","article-title":"Multiple Myeloma: Risk adapted use of plerixafor for stem cell mobilization prior to autologous stem cell transplantation is effective and cost efficient","volume":"22","author":"Prakash","year":"2022","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"ref_42","first-page":"103303","article-title":"Plerixafor strategies for autologous hematopoietic cell transplant mobilization: A comparison of efficacy and cost","volume":"2021","author":"Chen","year":"2021","journal-title":"Transfus. Apher. Sci."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"102819","DOI":"10.1016\/j.transci.2020.102819","article-title":"A comparison of chemo-free strategy with G-CSF plus plerixafor on demand versus intermediate-dose cyclophosphamide and G-CSF as PBSC mobilization in newly diagnosed multiple myeloma patients: An Italian explorative cost analysis","volume":"5","author":"Laszlo","year":"2020","journal-title":"Transfus. Apher. Sci."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"770.e1","DOI":"10.1016\/j.jtct.2021.06.016","article-title":"The efficacy and safety of chemotherapy-based stem cell mobilization in multiple myeloma patients who are poor responders to induction: The Mayo Clinic Experience","volume":"27","author":"Vaxman","year":"2021","journal-title":"Transpl. Cell Ther."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1038\/s41409-018-0117-5","article-title":"Advantages of non-cryopreserved autologous hematopoietic stem cell transplantation against a cryopreserved strategy","volume":"53","author":"Sarmiento","year":"2018","journal-title":"Bone Marrow Transpl."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1182\/blood-2020-143049","article-title":"Fresh versus cryopreserved peripheral stem cell for autologous transplantation in multiple myeloma: An analysis of short-term outcomes","volume":"136","author":"Joseph","year":"2020","journal-title":"Blood"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"e31","DOI":"10.1016\/j.bbmt.2018.08.007","article-title":"Use of Non-Cryopreserved Peripheral Blood Stem Cells Is Associated with Adequate Engraftment in Patients with Multiple Myeloma Undergoing an Autologous Transplant","volume":"24","author":"Kulkarni","year":"2018","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/j.jcyt.2020.12.016","article-title":"Non-cryopreserved hematopoietic stem cells in autograft patients with lymphoma: A matched-pair analysis comparing a single center experience with the use of cryopreserved stem cells reported to the European Society for Blood and Marrow Transplantation registry","volume":"23","author":"Bekadja","year":"2021","journal-title":"Cytotherapy"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"2382","DOI":"10.1111\/j.1537-2995.2012.03585.x","article-title":"An automatic wash method for dimethyl sulfoxide removal in autologous hematopoietic stem cell transplantation decreases the adverse effects related to infusion","volume":"52","author":"Blanquer","year":"2012","journal-title":"Transfusion"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1093\/annonc\/mdm069","article-title":"Feasibility and safety of autotransplants with noncryopreserved marrow or peripheral blood stem cells: A systematic review","volume":"18","author":"Wannesson","year":"2007","journal-title":"Ann. Oncol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.clml.2013.09.001","article-title":"High-dose chemotherapy and autologous stem cell transplantation in multiple myeloma: A single institution experience at All India Institute of Medical Sciences, New Delhi, using non-cryopreserved peripheral blood stem cells","volume":"14","author":"Kayal","year":"2014","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1038\/s41409-017-0047-7","article-title":"Freezing the graft is not necessary for autotransplants for plasma cell myeloma and lymphomas","volume":"53","author":"Gale","year":"2018","journal-title":"Bone Marrow Transpl."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1038\/s41409-018-0174-9","article-title":"Hematopoietic stem cell transplantation using non-cryopreserved peripheral blood stem cells graft is effective in multiple myeloma and lymphoma","volume":"53","author":"Naithani","year":"2018","journal-title":"Bone Marrow Transpl."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"e861","DOI":"10.1016\/S2352-3026(20)30323-9","article-title":"Bortezomib, thalidomide, and dexamethasone followed by double autologous haematopoietic stem-cell transplantation for newly diagnosed multiple myeloma (GIMEMA-MMY-3006): Long-term follow-up analysis of a randomised phase 3, open-label study","volume":"7","author":"Tacchetti","year":"2020","journal-title":"Lancet Haematol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1111\/ejh.12829","article-title":"Association between complete response and outcomes in transplant-eligible myeloma patients in the era of novel agents","volume":"98","author":"Londhe","year":"2017","journal-title":"Eur. J. Haematol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1001\/jamaoncol.2016.3160","article-title":"Association of minimal residual disease with superior survival outcomes in patients with multiple myeloma: A meta-analysis","volume":"3","author":"Munshi","year":"2017","journal-title":"JAMA Oncol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"5988","DOI":"10.1182\/bloodadvances.2020002827","article-title":"A large meta-analysis establishes the role of MRD negativity in long-term survival outcomes in patients with multiple myeloma","volume":"4","author":"Munshi","year":"2020","journal-title":"Blood Adv."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1200\/JCO.19.01231","article-title":"GEM (Grupo Espa\u00f1ol de Mieloma)\/PETHEMA (Programa Para el Estudio de la Terap\u00e9utica en Hemopat\u00edas Malignas) Cooperative Study Group. Measurable residual disease by next-generation flow cytometry in multiple myeloma","volume":"38","author":"Paiva","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1182\/blood-2021-151557","article-title":"Assessment of treatment response by ife, next generation flow cytometry and mass spectrometry coupled with liquid chromatography in the GEM2021MENOS65 clinical trial","volume":"138","author":"Puig","year":"2021","journal-title":"Blood"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1182\/blood-2021-147897","article-title":"Daratumumab (DARA) with bortezomib, thalidomide, and dexamethasone (VTd) in transplant-eligible patients (Pts) with newly diagnosed multiple myeloma (NDMM): Analysis of minimal residual disease (MRD) negativity in Cassiopeia Part 1 and Part 2","volume":"138","author":"Sonneveld","year":"2021","journal-title":"Blood"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1182\/blood-2021-149024","article-title":"Daratumumab (DARA) plus lenalidomide, bortezomib, and dexamethasone (RVd) in patients with transplant-eligible newly diagnosed multiple myeloma: Updated analysis of Griffin after 24 months of maintenance","volume":"138","author":"Laubach","year":"2021","journal-title":"Blood"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"3613","DOI":"10.1200\/JCO.21.01045","article-title":"Consolidation and maintenance in newly diagnosed multiple myeloma","volume":"39","author":"Sonneveld","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1038\/s41408-021-00498-0","article-title":"Minimal residual disease assessment by multiparameter flow cytometry in transplant-eligible myeloma in the EMN02\/HOVON 95 MM trial","volume":"11","author":"Oliva","year":"2021","journal-title":"Blood Cancer J."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1200\/JCO.18.00685","article-title":"Autologous transplantation, consolidation, and maintenance therapy in multiple myeloma: Results of the BMT CTN 0702 Trial","volume":"37","author":"Stadtmauer","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"8506","DOI":"10.1200\/JCO.2020.38.15_suppl.8506","article-title":"Long-term follow-up of BMT CTN 0702 (STaMINA) of postautologous hematopoietic cell transplantation (autoHCT) strategies in the upfront treatment of multiple myeloma (MM)","volume":"38","author":"Parameswaran","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1182\/blood-2020-134538","article-title":"Early versus late autologous stem cell transplant in newly diagnosed multiple myeloma: Long-term follow-up analysis of the IFM 2009 trial","volume":"136","author":"Perrot","year":"2020","journal-title":"Blood"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"OAB-003","DOI":"10.1016\/S2152-2650(21)02077-2","article-title":"CARDAMON: Carfilzomib (K) maintenance following autologous stem cell transplant (ASCT) or carfilzomib-cyclophosphamide-dexamethasone (KCd) consolidation for newly diagnosed (NDTE) multiple myeloma (MM)","volume":"21","author":"Popat","year":"2021","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1182\/blood-2021-146060","article-title":"Updated results from CARTITUDE-1: Phase 1b\/2 study of ciltacabtagene autoleucel, a B-Cell Maturation Antigen-directed Chimeric Antigen Receptor T cell therapy, in patients with relapsed\/refractory multiple myeloma","volume":"138","author":"Martin","year":"2021","journal-title":"Blood"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"1782","DOI":"10.1056\/NEJMoa1114138","article-title":"Lenalidomide maintenance after stem-cell transplantation for multiple myeloma","volume":"366","author":"Attal","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"e431","DOI":"10.1016\/S2352-3026(17)30140-0","article-title":"Updated analysis of CALGB (Alliance) 100104 assessing lenalidomide versus placebo maintenance after single autologous stem-cell transplantation for multiple myeloma: A randomised, double-blind, phase 3 trial","volume":"4","author":"Holstein","year":"2017","journal-title":"Lancet Haematol."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"3279","DOI":"10.1200\/JCO.2017.72.6679","article-title":"Lenalidomide maintenance after autologous stem-cell transplantation in newly diagnosed multiple myeloma: A meta-analysis","volume":"35","author":"McCarthy","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/S1470-2045(18)30687-9","article-title":"Lenalidomide maintenance versus observation for patients with newly diagnosed multiple myeloma (Myeloma XI): A multicentre, open-label, randomised, phase 3 trial","volume":"20","author":"Jackson","year":"2019","journal-title":"Lancet Oncol."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1038\/s41375-020-0724-1","article-title":"Response-adapted lenalidomide maintenance in newly diagnosed myeloma: Results from the phase III GMMG-MM5 trial","volume":"34","author":"Goldschmidt","year":"2020","journal-title":"Leukemia"},{"key":"ref_74","first-page":"OAB-015","article-title":"Minimal residual disease following autologous cell transplant for myeloma patients in the Myeloma XI trial: Prognostic significance and the impact of lenalidomide maintenance and molecular risk","volume":"21","author":"Pawlyn","year":"2021","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"e422","DOI":"10.1016\/S2352-3026(21)00130-7","article-title":"Dynamics of minimal residual disease in patients with multiple myeloma on continuous lenalidomide maintenance: A single-arm, single-centre, phase 2 trial","volume":"8","author":"Diamond","year":"2021","journal-title":"Lancet Haematol."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1038\/leu.2017.211","article-title":"Bortezomib before and after high-dose therapy in myeloma: Long-term results from the phase III HOVON-65\/GMMG-HD4 trial","volume":"32","author":"Goldschmidt","year":"2018","journal-title":"Leukemia"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41408-020-00390-3","article-title":"Lenalidomide versus bortezomib maintenance after frontline autologous stem cell transplantation for multiple myeloma","volume":"11","author":"Baertsch","year":"2021","journal-title":"Blood Cancer J."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/S0140-6736(18)33003-4","article-title":"Oral ixazomib maintenance following autologous stem cell transplantation (TOURMALINE-MM3): A double-blind, randomised, placebo-controlled phase 3 trial","volume":"393","author":"Dimopoulos","year":"2019","journal-title":"Lancet"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1182\/blood-2021-146798","article-title":"Ixazomib plus lenalidomide\/dexamethasone (IRd) versus lenalidomide\/dexamethasone (Rd) maintenance after autologous stem cell transplant in patients with newly diagnosed multiple myeloma: Results of the Spanish GEM2014MAIN Trial","volume":"138","author":"Rosinol","year":"2021","journal-title":"Blood"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.1016\/S1470-2045(21)00428-9","article-title":"Maintenance with daratumumab or observation following treatment with bortezomib, thalidomide, and dexamethasone with or without daratumumab and autologous stem-cell transplant in patients with newly diagnosed multiple myeloma (CASSIOPEIA): An open-label, randomised, phase 3 trial","volume":"22","author":"Moreau","year":"2021","journal-title":"Lancet Oncol."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"1730","DOI":"10.6004\/jnccn.2020.7673","article-title":"Defining and managing high-risk multiple myeloma: Current concepts","volume":"18","author":"Costa","year":"2020","journal-title":"J. Natl. Compr. Cancer Netw."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"100887","DOI":"10.1016\/j.blre.2021.100887","article-title":"Knowing the unknowns in high risk multiple myeloma","volume":"51","author":"Derman","year":"2022","journal-title":"Blood Rev."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"e4","DOI":"10.1016\/S2352-3026(20)30361-6","article-title":"High-risk myeloma: A challenge to define and to determine the optimal treatment","volume":"8","author":"Pawlyn","year":"2021","journal-title":"Lancet Haematol."},{"key":"ref_84","first-page":"467","article-title":"Impact of chromosome 1 abnormalities among patients with newly diagnosed multiple myeloma: A subgroup analysis from the Endurance (ECOG-ACRIN E1A11) trial","volume":"138","author":"Schmidt","year":"2021","journal-title":"Blood"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"OAB-004","DOI":"10.1016\/S2152-2650(21)02078-4","article-title":"Carfilzomib-based induction\/consolidation with or without autologous transplant and lenalidomide (R) or carfilzomib-lenalidomide (KR) maintenance: Efficacy in high-risk patients of the FORTE study","volume":"21","author":"Mina","year":"2021","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"8000","DOI":"10.1200\/JCO.2021.39.15_suppl.8000","article-title":"Upfront autologous stem cell transplantation (ASCT) versus carfilzomib-cyclophosphamide-dexamethasone (KCd) consolidation with K maintenance in transplant-eligible, newly diagnosed (NDTE) multiple myeloma (MM)","volume":"39","author":"Yong","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"2723","DOI":"10.1182\/blood-2021-148533","article-title":"Daratumumab plus lenalidomide, bortezomib, and dexamethasone (D-VRd) in transplant-eligible newly diagnosed multiple myeloma patients: A subgroup analysis of Griffin","volume":"138","author":"Anderson","year":"2021","journal-title":"Blood"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1182\/blood-2021-145494","article-title":"Daratumumab, carfilzomib, lenalidomide and dexamethasone (Dara-KRd), autologous transplantation and MRD response-adapted consolidation and treatment cessation. Final primary endpoint analysis of the Master trial","volume":"138","author":"Costa","year":"2021","journal-title":"Blood"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1182\/blood.2020006731","article-title":"Deep MRD profiling defines outcome and unveils different modes of treatment resistance in standard- and high-risk myeloma","volume":"137","author":"Goicoechea","year":"2021","journal-title":"Blood"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"e45","DOI":"10.1016\/S2352-3026(20)30354-9","article-title":"Bortezomib, lenalidomide, and dexamethasone with or without elotuzumab in patients with untreated, high-risk multiple myeloma (SWOG-1211): Primary analysis of a randomised, phase 2 trial","volume":"8","author":"Usmani","year":"2021","journal-title":"Lancet Haematol."},{"key":"ref_91","first-page":"S183","article-title":"Updated interim analysis of the GMMG-CONCEPT trial investigating isatuximab, carfilzomib, lenalidomide, and dexamethasone (Isa-KRD) in front-line treatment of high-risk multiple myeloma","volume":"5","author":"Leypoldt","year":"2021","journal-title":"Hemasphere"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1182\/blood-2021-144990","article-title":"Daratumumab, cyclophosphamide, bortezomib, lenalidomide, dexamethasone (Dara-CVRd), v-augmented autologous stem cell transplant (V-ASCT) and Dara-Vrd consolidation in ultra-high risk (UHiR) newly diagnosed myeloma (NDMM) and primary plasma cell leukemia (pPCL) compared with Myeloma XI\/XI+ trial treatment for Uhir MM: The UK Optimum\/Muknine Trial","volume":"138","author":"Kaiser","year":"2021","journal-title":"Blood"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1038\/s41409-020-01007-w","article-title":"Upfront stem cell transplantation for newly diagnosed multiple myeloma with del(17p) and t(4;14): A study from the CMWP-EBMT","volume":"56","author":"Gagelmann","year":"2021","journal-title":"Bone Marrow Transpl."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.1016\/j.bbmt.2015.09.016","article-title":"American Society of Blood and Marrow Transplantation, European Society of Blood and Marrow Transplantation, Blood and Marrow Transplant Clinical Trials Network, and International Myeloma Working Group Consensus Conference on salvage hematopoietic cell transplantation in patients with relapsed multiple myeloma","volume":"21","author":"Giralt","year":"2015","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"e340","DOI":"10.1016\/S2352-3026(16)30049-7","article-title":"The effect of salvage autologous stem-cell transplantation on overall survival in patients with relapsed multiple myeloma (final results from BSBMT\/UKMF Myeloma X Relapse [Intensive]): A randomised, open-label, phase 3 trial","volume":"3","author":"Cook","year":"2016","journal-title":"Lancet Haematol."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1038\/s41375-020-0948-0","article-title":"Salvage autologous transplant and lenalidomide maintenance vs. lenalidomide\/dexamethasone for relapsed multiple myeloma: The randomized GMMG phase III trial ReLApsE. German Myeloma Multicenter Group (GMMG)","volume":"35","author":"Goldschmidt","year":"2021","journal-title":"Leukemia"}],"container-title":["Cells"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2073-4409\/11\/4\/606\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T22:17:21Z","timestamp":1760134641000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2073-4409\/11\/4\/606"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,10]]},"references-count":96,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2022,2]]}},"alternative-id":["cells11040606"],"URL":"https:\/\/doi.org\/10.3390\/cells11040606","relation":{},"ISSN":["2073-4409"],"issn-type":[{"value":"2073-4409","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,2,10]]}}}